• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol. The impact of laryngopharyngeal reflux disease on 95 hospitalized patients with COVID-19 in Wuhan, China: A retrospective study

tetano

Editor, Senior Moderator
J Med Virol. 2020 May 12. doi: 10.1002/jmv.25998. [Epub ahead of print]
The impact of laryngopharyngeal reflux disease on 95 hospitalized patients with COVID-19 in Wuhan, China: A retrospective study.


Jiang G[SUP]1[/SUP], Cai Y[SUP]2[/SUP], Yi X[SUP]3[/SUP], Li Y[SUP]3[/SUP], Lin Y[SUP]4[/SUP], Li Q[SUP]5[/SUP], Xu J[SUP]6[/SUP], Ke M[SUP]1[/SUP], Xue K[SUP]1[/SUP].

Author information




Abstract

BACKGROUND:

Studies have demonstrated that comorbidities, especially cardiovascular and endocrine diseases, correlated with poorer clinical outcomes. However, the impact of digestive system diseases have not been issued. The aim of this study is to determine the impact of laryngopharyngeal reflux disease (LPRD) on hospitalized patients with COVID-19.
METHODS:

We extracted clinical data regarding 95 patients in Jin-yin tan hospital, Wuhan, China between January 26[SUP]th[/SUP] , 2020 and February 21[SUP]st[/SUP] . The Reflux Symptom Index (RSI) was used to assess the presence and severity of LPRD. A RSI >13 is considered to be abnormal.
RESULTS:

A total of 95 patients with COVID-19 were enrolled, with 61.1% (58/95), 32.6% (31/95), and 6.3% (6/95) being moderately ill, severely ill, and critically ill, respectively. In this study, 38.9% (37/95) of the patient had a RSI score over 13, which was indicative of LPRD. In a univariable analysis, the age and RSI scores of severely or critically ill patients were statistically significantly higher than patients with moderate disease (p=0.026 and p=0.005, respectively). After controlling for age difference in a multivariable model, the RSI>13, compared with RSI=0, was associated with significantly higher risk of severe infection (p<0.001; OR = 11.411, 95% CI 2.95-42.09) and critical infection (p=0.028; OR = 19.61, 95% CI 1.38-277.99).
CONCLUSIONS:

Among hospitalized patients with COVID-19, RSI score greater than 13, indicative of LPRD, correlated with poorer clinical outcomes. The prevalence of LPRD may be higher than the general population, which indicated that COVID-19 can impair the upper esophageal sphincter and aggravate reflux. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.



KEYWORDS:

COVID-19; laryngopharyngeal reflux disease; severe acute respiratory syndrome coronavirus 2


PMID:32396239DOI:10.1002/jmv.25998
 
Back
Top Bottom